Metronomic capecitabine combined with aromatase inhibitors for new chemoendocrine treatment of advanced breast cancer: a phase II clinical trial

2018 ◽  
Vol 173 (2) ◽  
pp. 407-415 ◽  
Author(s):  
Jian-wei Li ◽  
Wen-jia Zuo ◽  
Diana Ivanova ◽  
Xiao-qing Jia ◽  
Li Lei ◽  
...  
1988 ◽  
Vol 74 (1) ◽  
pp. 53-56 ◽  
Author(s):  
Tiping Zhao ◽  
Guifen He

An antiandrogenic agent flutamide was used in the treatment of one male and 14 female postmenopausal breast cancer patients. Only a mild and transient response was seen in 2 female patients. Therefore, flutamide cannot be used solely in the treatment of female postmenopausal breast cancer.


2018 ◽  
Vol 36 (15_suppl) ◽  
pp. TPS1114-TPS1114
Author(s):  
Juan De La Haba ◽  
Angel Guerrero-Zotano ◽  
Jose Alejandro Perez-Fidalgo ◽  
Santiago Gonzalez Santiago ◽  
Montserrat Muñoz ◽  
...  

Author(s):  
Leiping Wang ◽  
Jun Cao ◽  
Chunlei Li ◽  
Xiaodong Wang ◽  
Yannan Zhao ◽  
...  

SummaryPurpose. This trial aimed to evaluate the efficacy and safety of mitoxantrone hydrochloride liposome injection (Lipo-MIT) in advanced breast cancer (ABC). Methods. In this randomized, open-label, active-controlled, single-center, phase II clinical trial, eligible patients were randomized in a ratio of 1:1 to receive Lipo-MIT or mitoxantrone hydrochloride injection (MIT) intravenously. The primary endpoint was objective response rate (ORR). The secondary endpoints were disease control rate (DCR), progression-free survival (PFS), and safety outcomes. Results. Sixty patients were randomized to receive Lipo-MIT or MIT. The ORR was 13.3% (95% confidence interval (CI): 3.8–30.7%) for Lipo-MIT and 6.7% (95% CI: 0.8–22.1%) for MIT. The DCR was 50% (95% CI: 31.3–68.7%) with Lipo-MIT vs. 30% (95% CI: 14.7–49.4%) with MIT. The median PFS was 1.92 months (95% CI: 1.75–3.61) for Lipo-MIT and 1.85 months (95% CI: 1.75–2.02) for MIT. The most common toxicity was myelosuppression. Lipo-MIT resulted in an incidence of 86.7% of leukopenia and 80.0% of neutropenia, which was marginally superior to MIT (96.7% and 96.7%, respectively). Lipo-MIT showed a lower incidence of cardiovascular events (13.3% vs. 20.0%) and increased cardiac troponin T (3.3% vs. 36.7%); but higher incidence of anemia (76.7% vs. 46.7%), skin hyperpigmentation (66.7% vs. 3.3%), and fever (23.3% vs. 10.0%) than MIT. Conclusions The clinical benefit parameters of Lipo-MIT and MIT were comparable. Lipo-MIT provided a different toxicity profile, which might be associated with the altered distribution of the drug. Additional study is needed to elucidate the potential benefit of Lipo-MIT in ABC. Clinical trial registration. This study is registered with ClinicalTrials.gov (No. NCT02596373) on Nov 4, 2015.


2007 ◽  
Vol 25 (6) ◽  
pp. 545-551 ◽  
Author(s):  
Sheri K. Dennison ◽  
Samuel A. Jacobs ◽  
John W. Wilson ◽  
Janell Seeger ◽  
Terrence P. Cescon ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document